Clinical Trial

Itraconazole Therapy In Bronchiectasis With Airway Mold

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the feasibility of itraconazole therapy in patients with bronchiectasis and airway mold. Feasibility will be assessed through recruitment success, treatment adherence, tolerability, and participant retention. The study will also explore the impact on respiratory symptoms and airway microbiome diversity.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-12; most recent amendment 2026-05-27.
Status change: Not Yet Recruiting → Recruiting 2026-02-08
Trial Details
NCT Number NCT07283497
Lead Sponsor Mayo Clinic
Conditions Bronchiectasis, Fungal Infection of Upper Respiratory Tract
Enrollment 30 participants
Start Date 2026-06-20
Primary Completion 2030-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-29